Skip to content

A Clinical Study to Evaluate the Maximum Maxillary Bite Force (BF) When Using Two Novel Denture Adhesives Compared to Using No-Adhesive

A Randomized, Single-Blind Clinical Study Assessing the Maximum Maxillary Bite Force When Using Two Novel Denture Adhesives Compared to Using No-Adhesive

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05173974
Enrollment
45
Registered
2021-12-30
Start date
2022-02-08
Completion date
2022-07-12
Last updated
2024-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Denture Retention

Brief summary

The purpose of this study is to investigate the hold properties of two experimental denture adhesives using established maximum incisal BF methodology.

Detailed description

This will be a single-centre, controlled, randomized, single-blind (with respect to the examiner performing the incisal BF measurements), 4-treatment, 4- period, cross-over study to evaluate the maximum maxillary BF in a population of full maxillary denture wearers. A currently marketed denture adhesive will be used as a positive control, whilst use of no adhesive will be employed as a negative control.

Interventions

A single application of 1 gram of Super Poligrip Free will be applied topically to oral tissues via the upper denture.

A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.

A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.

Sponsors

HALEON
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DEVICE_FEASIBILITY
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed. * A participant who is willing and able to comply with scheduled visits, and other study procedures. * A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements. * A participant with a completely edentulous maxillary arch restored with a conventional maxillary full denture with an acrylic base. The maxillary denture prosthesis must fulfil all of the following: 1. At least moderately well-fitting (Kapur Index, Olshan Modification: retention score Greater than or equal to (\>=)2, stability score \>=2) at the Screening (V1) visit, 2. Is well made (according to the well-made assessment). * A participant with BF measurements which satisfy all the following criteria: 1. The qualifying BF measurements (without adhesive) at V1 (Screening) must be less than or equal to (=\<) 9lbs. 2. At least 2 of the 4 qualifying BF measurements (without adhesive) at V1 (Screening) must be reproducible (within +-2lbs). 3. The Baseline BF measurement (without adhesive) at V2-5 must be \<=9lbs. 4. The Baseline BF measurement (without adhesive) at V2-5 and at least 1 of the 3 practice BF measurements must be within +-2lbs of each other. * A participant who is dentate in the mandibular arch or has a partial or full denture in the mandibular arch that is: 1. sufficiently stable, in the opinion of the investigator, to enable the bite force determination to be performed. 2. well made (according to the well-made assessment).

Exclusion criteria

* A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a GlaxoSmithKline Consumer Healthcare (GSK CH) employee directly involved in the conduct of the study or a member of their immediate family. * A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to Visit 1 and/or during study participation. * A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or experimental product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study. * A participant who is pregnant (self-reported) or intending to become pregnant over the duration of the study. * A participant who is breastfeeding. * A participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. * A participant unwilling or unable to comply with the Lifestyle Considerations. * A participant who is currently taking or has taken a bisphosphonate drug (that is (i.e.), Fosamax, Actonel, Boniva). * A participant who uses any medication or has a condition (e.g. insulin dependent diabetes) that, in the opinion of the investigator, would interfere with the conduct of the study. * A participant who has any clinically significant or relevant oral abnormality (for example (e.g.) temporomandibular joint \[TMJ\] problems or tooth abnormalities) that, in the opinion of the investigator, could affect the BF measurements or participant safety. * A participant who has any condition or medication which, in the opinion of the investigator, is currently causing xerostomia or which could interfere with the conduct of the study. * A participant with a recent history (within the last year) of alcohol or other substance abuse. * A participant with Oral soft tissue (OST) examination findings (at V1) such as stomatitis, open sores, lesions, cavitied caries lesions, redness or swelling which in the opinion of the investigator, could interfere with the conduct of the study. * A participant who has previously been enrolled in this study. * A participant who is unable to comply with study requirements and/or who is not able to reliably perform a valid bite at the examiner's discretion. * A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Area Over Baseline Over 12 Hours (AOB 0-12) to Compare Maximum Incisal Bite ForceBaseline and up to 12 hoursNatural logged incisal Bite Force (BF) measurements were performed to analyze the denture dislodgement as measure of denture adhesive hold efficacy. All BF measurements were conducted by an examiner. AOB 0-12 was used to assess the incisal BF and defined as (Area under the Curve \[AUC\]0-12) divided by 12 minus baseline BF (pounds \[lbs\]). AUC was calculated from 0 to 12 hours using the trapezoid method; denoted as AUC 0-12. This transformation was carried out to return the measurement to the same scale as the original observation. AOB 0-12 was analyzed for each of the three treatments in comparison to no denture adhesive treatment group. Higher values of AOB 0-12 demonstrate a stronger bite force over time than lower values. Baseline was defined as BF (lbs) recorded at hour 0 (pre-treatment).

Secondary

MeasureTime frameDescription
Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFBaseline, at 0.5, 1, 3, 6 and 9 hoursNatural logged incisal BF measurements were performed to analyze the denture dislodgement as measure of denture adhesive hold efficacy. All BF measurements were conducted by an examiner. AOB 0-t was defined as AUC 0-t divided by t minus baseline BF (lbs), where t is equal to 0.5, 1, 3, 6 and 9 hours. AUC was calculated from 0 to t hours using the trapezoid method; denoted as AUC 0-t. This transformation was carried out to return the measurement to the same scale as the original observation. AOB for 0.5, 1, 3, 6 and 9 hours were analyzed using the trapezoid method. AOB 0-0.5, AOB 0-1, AOB 0-3, AOB 0-6, AOB 0-9 were analyzed for each of the three treatments in comparison to no adhesive treatment group. Higher values of AOB demonstrate a stronger bite force over time than lower values. Baseline was defined as BF (lbs) recorded at hour 0 (pre-treatment).

Countries

United States

Participant flow

Recruitment details

All participants were recruited at a single center in United States of America (USA).

Pre-assignment details

A total of 52 participants were screened, of which 45 were enrolled (7 screened participants failed to meet the required criteria for study participation). Forty-three participants were randomized to study treatment (2 enrolled participants were not randomized due to lost to follow-up prior to treatment assignment) and 41 participants completed the study.

Participants by arm

ArmCount
Overall Study Participants
Participants received a single oral topical application of 1.00 +- 0.05 gram of Experimental Denture Adhesive 1, Experimental Denture Adhesive 2, Positive control (Super Poligrip Free Denture Adhesive) to the upper denture or Negative control (No Denture Adhesive) as per randomization schedule. Study products were applied by site study staff, to clean upper denture fit surface in a pattern consistent with product label and application instructions.
43
Total43

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Period 2 (Visit 3, 1 Day)Baseline bite was not eligible0001
Period 4 (Visit 5, 1 Day)Baseline bite was not eligible0100

Baseline characteristics

CharacteristicOverall Study Participants
Age, Continuous70.1 years
STANDARD_DEVIATION 8.7
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
43 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
24 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
18 Participants
Sex: Female, Male
Female
28 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 410 / 420 / 420 / 42
other
Total, other adverse events
6 / 413 / 424 / 423 / 42
serious
Total, serious adverse events
0 / 410 / 420 / 420 / 42

Outcome results

Primary

Area Over Baseline Over 12 Hours (AOB 0-12) to Compare Maximum Incisal Bite Force

Natural logged incisal Bite Force (BF) measurements were performed to analyze the denture dislodgement as measure of denture adhesive hold efficacy. All BF measurements were conducted by an examiner. AOB 0-12 was used to assess the incisal BF and defined as (Area under the Curve \[AUC\]0-12) divided by 12 minus baseline BF (pounds \[lbs\]). AUC was calculated from 0 to 12 hours using the trapezoid method; denoted as AUC 0-12. This transformation was carried out to return the measurement to the same scale as the original observation. AOB 0-12 was analyzed for each of the three treatments in comparison to no denture adhesive treatment group. Higher values of AOB 0-12 demonstrate a stronger bite force over time than lower values. Baseline was defined as BF (lbs) recorded at hour 0 (pre-treatment).

Time frame: Baseline and up to 12 hours

Population: mITT population. Only those participants available at the indicated timepoints were analyzed.

ArmMeasureValue (MEAN)Dispersion
Experimental Denture Adhesive 1Area Over Baseline Over 12 Hours (AOB 0-12) to Compare Maximum Incisal Bite Force0.87 lbsStandard Deviation 0.8
Experimental Denture Adhesive 2Area Over Baseline Over 12 Hours (AOB 0-12) to Compare Maximum Incisal Bite Force0.69 lbsStandard Deviation 0.7
Positive ControlArea Over Baseline Over 12 Hours (AOB 0-12) to Compare Maximum Incisal Bite Force0.89 lbsStandard Deviation 0.86
Negative ControlArea Over Baseline Over 12 Hours (AOB 0-12) to Compare Maximum Incisal Bite Force0.59 lbsStandard Deviation 0.71
p-value: 0.03795% CI: [0.01, 0.29]ANCOVA
p-value: 0.04495% CI: [0, 0.28]ANCOVA
p-value: 0.00595% CI: [0.06, 0.3]ANCOVA
Secondary

Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BF

Natural logged incisal BF measurements were performed to analyze the denture dislodgement as measure of denture adhesive hold efficacy. All BF measurements were conducted by an examiner. AOB 0-t was defined as AUC 0-t divided by t minus baseline BF (lbs), where t is equal to 0.5, 1, 3, 6 and 9 hours. AUC was calculated from 0 to t hours using the trapezoid method; denoted as AUC 0-t. This transformation was carried out to return the measurement to the same scale as the original observation. AOB for 0.5, 1, 3, 6 and 9 hours were analyzed using the trapezoid method. AOB 0-0.5, AOB 0-1, AOB 0-3, AOB 0-6, AOB 0-9 were analyzed for each of the three treatments in comparison to no adhesive treatment group. Higher values of AOB demonstrate a stronger bite force over time than lower values. Baseline was defined as BF (lbs) recorded at hour 0 (pre-treatment).

Time frame: Baseline, at 0.5, 1, 3, 6 and 9 hours

Population: mITT population. Only those participants available at the indicated timepoints were analyzed.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental Denture Adhesive 1Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-10.64 lbsStandard Deviation 0.52
Experimental Denture Adhesive 1Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-60.86 lbsStandard Deviation 0.75
Experimental Denture Adhesive 1Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-30.84 lbsStandard Deviation 0.65
Experimental Denture Adhesive 1Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-90.85 lbsStandard Deviation 0.79
Experimental Denture Adhesive 1Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-0.50.40 lbsStandard Deviation 0.36
Experimental Denture Adhesive 2Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-30.65 lbsStandard Deviation 0.63
Experimental Denture Adhesive 2Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-0.50.34 lbsStandard Deviation 0.4
Experimental Denture Adhesive 2Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-10.51 lbsStandard Deviation 0.56
Experimental Denture Adhesive 2Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-60.71 lbsStandard Deviation 0.68
Experimental Denture Adhesive 2Area Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-90.71 lbsStandard Deviation 0.69
Positive ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-10.71 lbsStandard Deviation 0.65
Positive ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-30.84 lbsStandard Deviation 0.74
Positive ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-0.50.47 lbsStandard Deviation 0.48
Positive ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-90.89 lbsStandard Deviation 0.85
Positive ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-60.88 lbsStandard Deviation 0.82
Negative ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-0.50.26 lbsStandard Deviation 0.37
Negative ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-60.58 lbsStandard Deviation 0.68
Negative ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-30.54 lbsStandard Deviation 0.63
Negative ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-90.58 lbsStandard Deviation 0.7
Negative ControlArea Over Baseline at 0.5, 1, 3, 6 And 9 Hours to Compare Maximum Incisal BFAOB 0-10.40 lbsStandard Deviation 0.52
p-value: 0.21895% CI: [-0.04, 0.17]ANCOVA
p-value: 0.03495% CI: [0.01, 0.21]ANCOVA
p-value: 0.00495% CI: [0.05, 0.25]ANCOVA
p-value: 0.05895% CI: [0, 0.24]ANCOVA
p-value: 0.01795% CI: [0.03, 0.27]ANCOVA
p-value: 0.00195% CI: [0.09, 0.33]ANCOVA
p-value: 0.00495% CI: [0.06, 0.3]ANCOVA
p-value: 0.0195% CI: [0.04, 0.27]ANCOVA
p-value: 0.00295% CI: [0.07, 0.31]ANCOVA
p-value: 0.02295% CI: [0.02, 0.29]ANCOVA
p-value: 0.01195% CI: [0.04, 0.3]ANCOVA
p-value: 0.00595% CI: [0.06, 0.33]ANCOVA
p-value: 0.03795% CI: [0.01, 0.27]ANCOVA
p-value: 0.01395% CI: [0.04, 0.3]ANCOVA
p-value: 0.00595% CI: [0.06, 0.32]ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026